Common use of Warrant Coverage Clause in Contracts

Warrant Coverage. The Company shall issue to ▇▇▇▇▇▇ or its designees at each Closing, warrants (the “▇▇▇▇▇▇ Warrants”) to purchase that number of shares of common stock of the Company equal to 5% of the aggregate number of shares of Common Stock placed in each Offering (if the Securities are convertible or include a “greenshoe” or “additional investment” option component, such shares of Common Stock underlying such Securities or options). If the Securities included in an Offering are non-convertible, the ▇▇▇▇▇▇ Warrants shall be determined by dividing the gross proceeds raised in such Offering divided by the then market price of the Common Stock. The ▇▇▇▇▇▇ Warrants shall have the same terms as the warrants issued to investors in the applicable Offering. If no warrants are issued to investors in an Offering, the ▇▇▇▇▇▇ Warrants shall be in a customary form reasonably acceptable to ▇▇▇▇▇▇, have a term of 5 years and an exercise price equal to 110% of the then market price of the Common Stock.

Appears in 3 contracts

Sources: Exclusive Agency Agreement (Cancer Genetics, Inc), Exclusive Agency Agreement (Cancer Genetics, Inc), Exclusive Agency Agreement (Cel Sci Corp)

Warrant Coverage. The Company shall issue to W▇▇▇▇▇▇▇▇▇ or its designees at each Closing, warrants (the “W▇▇▇▇▇▇▇▇▇ Warrants”) to purchase that number of shares of common stock of the Company equal to 5% of the aggregate number of shares of Common Stock placed in each Offering (if the Securities are convertible or include a “greenshoe” or “additional investment” option component, such shares of Common Stock underlying such Securities or options). If the Securities included in an Offering are non-convertible, the W▇▇▇▇▇▇▇▇▇ Warrants shall be determined by dividing the gross proceeds raised in such Offering divided by the then market price of the Common Stock. The W▇▇▇▇▇▇▇▇▇ Warrants shall have the same terms as the warrants issued to investors in the applicable Offering. If no warrants are issued to investors in an Offering, the W▇▇▇▇▇▇▇▇▇ Warrants shall be in a customary form reasonably acceptable to W▇▇▇▇▇▇▇▇▇, have a term of 5 years and an exercise price equal to 110% of the then market price of the Common Stock.

Appears in 2 contracts

Sources: Exclusive Agency Agreement (Tapimmune Inc), Exclusive Agency Agreement (Tapimmune Inc)

Warrant Coverage. The Company shall issue to R▇▇▇▇▇ or its designees at each Closing, warrants (the “R▇▇▇▇▇ Warrants”) to purchase that number of shares of common stock of the Company equal to 5% of the aggregate number of shares of Common Stock placed in each Offering (if the Securities are convertible or include a “greenshoe” or “additional investment” option component, such shares of Common Stock underlying such Securities or options). If the Securities included in an Offering are non-convertible, the R▇▇▇▇▇ Warrants shall be determined by dividing the gross proceeds raised in such Offering divided by the then market price of the Common Stock. The R▇▇▇▇▇ Warrants shall have the same terms as the warrants issued to investors in the applicable Offering. If no warrants are issued to investors in an Offering, the R▇▇▇▇▇ Warrants shall be in a customary form reasonably acceptable to R▇▇▇▇▇, have a term of 5 years and an exercise price equal to 110% of the then market price of the Common Stock.

Appears in 1 contract

Sources: Exclusive Agency Agreement (Biostage, Inc.)

Warrant Coverage. The Company shall issue to ▇▇▇▇▇▇▇▇▇▇ or its designees at each Closing, warrants (the "▇▇▇▇▇▇▇▇▇▇ Warrants") to purchase that number of shares of common stock of the Company equal to 57% of the aggregate number of shares of Common Stock placed in each Offering (if the Securities are convertible or include a "greenshoe" or "additional investment" option component, such shares of Common Stock underlying such Securities or options). If the Securities included in an Offering are non-convertible, the ▇▇▇▇▇▇▇▇▇▇ Warrants shall be determined by dividing the gross proceeds raised in such Offering divided by the then market price of the Common Stock. The ▇▇▇▇▇▇▇▇▇▇ Warrants shall have the same terms as the warrants issued to investors in the applicable Offering. If no warrants are issued to investors in an Offering, the ▇▇▇▇▇▇▇▇▇▇ Warrants shall be in a customary form reasonably acceptable to ▇▇▇▇▇▇▇▇▇▇, have a term of 5 years and an exercise price equal to 110% of the then market price of the Common Stock.

Appears in 1 contract

Sources: Exclusive Agency Agreement (Uranium Energy Corp)

Warrant Coverage. The Company shall issue to ▇▇▇▇▇▇ or its designees at each Closing, warrants (the “▇▇▇▇▇▇ Warrants”) to purchase that number of shares of common stock of the Company equal to 53 % of the aggregate number of shares of Common Stock placed in each Offering (if the Securities are convertible or include a “greenshoe” or “additional investment” option component, such shares of Common Stock underlying such Securities or options). If the Securities included in an Offering are non-convertible, the ▇▇▇▇▇▇ Warrants shall be determined by dividing the gross proceeds raised in such Offering divided by the then market price of the Common Stock. The ▇▇▇▇▇▇ Warrants shall have the same terms as the warrants issued to investors in the applicable Offering. If no warrants are issued to investors in an Offering, the ▇▇▇▇▇▇ Warrants shall be in a customary form reasonably acceptable to ▇▇▇▇▇▇, have a term of 5 years and an exercise price equal to 110% of the then market price of the Common Stock.

Appears in 1 contract

Sources: Exclusive Agency Agreement (BioPharmX Corp)

Warrant Coverage. The Company shall issue to ▇▇▇▇▇▇ or its designees at each Closing, warrants (the “▇▇▇▇▇▇ Warrants”) to purchase that number of shares of common stock of the Company equal to 5% of the aggregate number of shares of Common Stock placed in each the Offering (if the Securities are convertible or include a “greenshoe” or “additional investment” option component, such shares of Common Stock underlying such Securities or options). If the Securities included in an Offering are non-convertible, the ▇▇▇▇▇▇ Warrants shall be determined by dividing the gross proceeds raised in such Offering divided by the then market price of the Common Stock. The ▇▇▇▇▇▇ Warrants shall have the same terms as the warrants issued to investors in the applicable Offering. If no warrants are issued to investors in an Offering, the ▇▇▇▇▇▇ Warrants shall be in a customary form reasonably acceptable to ▇▇▇▇▇▇, have a term of 5 years and an exercise price equal to 110% of the then market price of the Common Stock.

Appears in 1 contract

Sources: Exclusive Agency Agreement (Biostage, Inc.)

Warrant Coverage. The Company shall issue to ▇▇▇▇▇▇ or its designees at each Closing, warrants (the "▇▇▇▇▇▇ Warrants") to purchase that number of shares of common stock of the Company equal to 58% of the aggregate number of shares of Common Stock placed in each Offering (if the Securities are convertible or include a "greenshoe" or "additional investment" option component, such shares of Common Stock underlying such Securities or options). If the Securities included in an Offering are non-convertible, the ▇▇▇▇▇▇ Warrants shall be determined by dividing the gross proceeds raised in such Offering divided by the then market price of the Common Stock. The ▇▇▇▇▇▇ Warrants shall have the same terms as the warrants issued to investors in the applicable Offering. If no warrants are issued to investors in an Offering, the ▇▇▇▇▇▇ Warrants shall be in a customary form reasonably acceptable to ▇▇▇▇▇▇, have a term of 5 years and an exercise price equal to 110% of the then market price of the Common Stock.

Appears in 1 contract

Sources: Exclusive Agency Agreement (Oxis International Inc)

Warrant Coverage. The Company shall issue to R▇▇▇▇▇ or its designees at each Closing, warrants (the “R▇▇▇▇▇ Warrants”) to purchase that number of shares of common stock of the Company equal to 54% of the aggregate number of shares of Common Stock placed in each Offering (if the Securities are convertible or include a “greenshoe” or “additional investment” option component, such shares of Common Stock underlying such Securities or options). If the Securities included in an Offering are non-convertible, the R▇▇▇▇▇ Warrants shall be determined by dividing the gross proceeds raised in such Offering divided by the then market price of the Common Stock. The R▇▇▇▇▇ Warrants shall have the same terms as the warrants issued to investors in the applicable Offering. If no warrants are issued to investors in an Offering, the R▇▇▇▇▇ Warrants shall be in a customary form reasonably acceptable to R▇▇▇▇▇, have a term of 5 years and an exercise price equal to 110% of the then market price of the Common Stock.

Appears in 1 contract

Sources: Exclusive Agency Agreement (Cel Sci Corp)

Warrant Coverage. The Company shall issue to ▇▇▇▇▇▇▇▇▇▇ or its designees at each Closing, warrants (the “▇▇▇▇▇▇▇▇▇▇ Warrants”) to purchase that number of shares of common stock of the Company equal to 54% of the aggregate number of shares of Common Stock placed in each Offering (if the Securities are convertible or include a “greenshoe” or “additional investment” option component, such shares of Common Stock underlying such Securities or options). If the Securities included in an Offering are non-convertible, the ▇▇▇▇▇▇▇▇▇▇ Warrants shall be determined by dividing the gross proceeds raised in such Offering divided by the then market price of the Common Stock. The ▇▇▇▇▇▇▇▇▇▇ Warrants shall have the same terms as the warrants issued to investors in the applicable Offering. If no warrants are issued to investors in an Offering, the ▇▇▇▇▇▇▇▇▇▇ Warrants shall be in a customary form reasonably acceptable to ▇▇▇▇▇▇▇▇▇▇, have a term of 5 3 years and an exercise price equal to 110(i) $10.00 in connection with the initial Offering only and (ii) 120% of the then market public offering price of the Common StockStock in any other Offering hereunder.

Appears in 1 contract

Sources: Exclusive Agency Agreement (Oramed Pharmaceuticals Inc.)